MedTrace Logo

Assessment of Efficacy of CR8020 and CR6261, Monoclonal Antibodies, Against Influenza Infection

NCT01992276 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2014-03-04

No results posted yet for this study

Summary

The purpose of this study is to evaluate the rate of decline in quantitative viral load measured in hospitalized patients with Influenza A infection

Conditions

Interventions

BIOLOGICAL

CR8020

30 mg/kg administered as a single 2-hour intravenous infusion on Day 1

BIOLOGICAL

CR6261

30 mg/kg administered as a single 2-hour intravenous infusion on Day 1

BIOLOGICAL

Placebo

Administered as a single 2-hour intravenous infusion on Day 1

Sponsors & Collaborators

  • Division of Microbiology and Infectious Diseases (DMID)

    collaborator UNKNOWN

  • National Institutes of Health (NIH)

    collaborator NIH

  • Crucell Holland BV

    lead INDUSTRY

Principal Investigators

  • Crucell Holland BV Clinical Trial · Crucell Holland BV

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2014-10-31
Completion
2015-02-28

Countries

  • United States
  • Australia
  • Belgium
  • Brazil
  • Bulgaria
  • Canada
  • France
  • Germany
  • Netherlands
  • South Africa
  • Spain
  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01992276 on ClinicalTrials.gov